Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Histological Outcomes And Jak-Stat Signalling In Ulcerative Colitis Patients Treated With Tofacitinib.
van Gennep S, Fung ICN, de Jong DC, Ramkisoen RK, Clasquin E, de Jong J, de Vries LCS, de Jonge WJ, Gecse KB, Löwenberg M, Woolcott JC, Mookhoek A, D'Haens GR. van Gennep S, et al. Among authors: woolcott jc. J Crohns Colitis. 2024 Mar 20:jjae031. doi: 10.1093/ecco-jcc/jjae031. Online ahead of print. J Crohns Colitis. 2024. PMID: 38506097 Free article.
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
Charles-Schoeman C, Fleischmann R, Mysler E, Greenwald M, Ytterberg SR, Koch GG, Bhatt DL, Wang C, Mikuls TR, Chen AS, Connell CA, Woolcott JC, Menon S, Chen Y, Lee K, Szekanecz Z. Charles-Schoeman C, et al. Among authors: woolcott jc. Arthritis Rheumatol. 2024 Mar 13. doi: 10.1002/art.42846. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 38481002
Presence of risk factors associated with colectomy among patients with ulcerative colitis: a post hoc analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program.
Rubin DT, Salese L, Cohen M, Kotze PG, Woolcott JC, Su C, Mundayat R, Paulissen J, Torres J, Long MD. Rubin DT, et al. Among authors: woolcott jc. Therap Adv Gastroenterol. 2023 Aug 7;16:17562848231189122. doi: 10.1177/17562848231189122. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37560161 Free PMC article.
Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
Dubinsky MC, Armuzzi A, Gecse KB, Ullman T, Bushmakin AG, DiBonaventura M, Cappelleri JC, Connelly SB, Woolcott JC, Salese L. Dubinsky MC, et al. Among authors: woolcott jc. Dig Dis. 2023;41(4):604-614. doi: 10.1159/000528788. Epub 2023 Jan 5. Dig Dis. 2023. PMID: 36603566 Free PMC article. Clinical Trial.
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panés J, Cohen SB. Winthrop KL, et al. Among authors: woolcott jc. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17. Rheumatol Ther. 2023. PMID: 36526796 Free PMC article.
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR. Hudesman DP, et al. Among authors: woolcott jc. Patient. 2023 Mar;16(2):95-103. doi: 10.1007/s40271-022-00603-w. Epub 2022 Nov 7. Patient. 2023. PMID: 36336750 Free PMC article. Clinical Trial.
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis.
de Vlam K, Mease PJ, Bushmakin AG, Fleischmann R, Ogdie A, Azevedo VF, Merola JF, Woolcott J, Cappelleri JC, Fallon L, Taylor PC. de Vlam K, et al. Among authors: woolcott j. Rheumatol Ther. 2022 Oct;9(5):1451-1464. doi: 10.1007/s40744-022-00482-5. Epub 2022 Sep 8. Rheumatol Ther. 2022. PMID: 36076054 Free PMC article.
Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
Haraoui B, Khraishi M, Choquette D, Lisnevskaia L, Teo M, Kinch C, Galos C, Roy P, Gruben D, Woolcott JC, Vaillancourt J, Sampalis JS, Keystone EC; Canadian Tofacitinib for Rheumatoid Arthritis Observational Investigators. Haraoui B, et al. Among authors: woolcott jc. Arthritis Care Res (Hoboken). 2023 Feb;75(2):240-251. doi: 10.1002/acr.24966. Epub 2022 Oct 10. Arthritis Care Res (Hoboken). 2023. PMID: 35678771 Free PMC article.
47 results